Table 2.
Comparison of recurrence and local recurrence in each treatment group
| Treatment | No | Yes | Multivariate-adjusted |
Adjusted by inverse probability of treatment weights |
||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | |||
| Recurrence | ||||||||
| RFA vs. TACE + RFA | ||||||||
| RFA | 24 (57.1) | 18 (42.9) | 1.000 | - | 0.776 | 1.000 | - | 0.563 |
| TACE + RFA | 31 (36.9) | 53 (63.1) | 1.089 | 0.605–1.962 | - | 0.866 | 0.533–1.409 | - |
| TACE vs. TACE + RFA | ||||||||
| TACE | 10 (17.3) | 48 (82.7) | 1.000 | - | 0.015 | 1.000 | - | 0.009 |
| TACE + RFA | 31 (36.9) | 53 (63.1) | 0.581 | 0.374–0.901 | - | 0.594 | 0.403–0.876 | - |
| RFA vs. TACE | ||||||||
| RFA | 24 (57.1) | 18 (42.9) | 1.000 | - | 0.005 | 1.000 | - | 0.047 |
| TACE | 10 (17.3) | 48 (82.7) | 2.543 | 1.322–4.895 | - | 1.671 | 1.006–2.775 | - |
| Local recurrence | ||||||||
| RFA vs. TACE + RFA | ||||||||
| RFA | 32 (76.1) | 10 (23.9) | 1.000 | - | 0.014 | 1.000 | - | 0.008 |
| TACE + RFA | 74 (88.1) | 10 (11.9) | 0.299 | 0.114–0.785 | - | 0.309 | 0.130–0.736 | - |
| TACE vs. TACE + RFA | ||||||||
| TACE | 42 (72.9) | 16 (27.1) | 1.000 | - | 0.019 | 1.000 | - | 0.011 |
| TACE + RFA | 74 (88.1) | 10 (11.9) | 0.354 | 0.149–0.840 | - | 0.352 | 0.158–0.787 | - |
| RFA vs. TACE | ||||||||
| RFA | 32 (76.1) | 10 (23.9) | 1.000 | - | 0.787 | 1.000 | - | 0.872 |
| TACE | 42 (72.9) | 16 (27.1) | 0.880 | 0.347–2.229 | - | 0.939 | 0.435–2.025 | - |
Values are presented as number (%). Adjusted for age, gender, cause, tumor size, tumor number, child class, α-fetoprotein. HR, hazard ratio; CI, confidence interval; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.